Clinical Trials Logo

Relapsed Acute Leukemia clinical trials

View clinical trials related to Relapsed Acute Leukemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT01701375 Terminated - Clinical trials for Refractory Acute Leukemia

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Start date: September 2012
Phase: Phase 1
Study type: Interventional

1.1 Primary Objectives - To determine the feasibility, tolerability, and toxicities of administering the selective CDK 4/6 inhibitor PD 0332991 prior to the combination of ara-C and Mitoxantrone for adults with relapsed and refractory acute leukemias and high risk myelodysplasias (MDS), including primary refractory disease - To determine the direct cytotoxic effects of single agent PD 0332991 on malignant blasts - To determine the maximal tolerated dose (MTD) of PD 0332991 in timed sequential combination with ara-C and Mitoxantrone - To determine if the timed sequential combination of PD 0332991 with ara-C and mitoxantrone can induce clinical responses in adults with relapsed or refractory acute leukemias and high-risk MDS 1.2 Secondary Objectives: - To determine the ability of PD 0332991 to directly induce apoptosis in malignant cell populations in vivo - To obtain pharmacodynamic (PD) data regarding the ability of PD 0332991 to arrest malignant cells in the G 1 phase of cell cycle, followed by synchronized release of those cells into S phase upon discontinuation of PD 0332991 and resultant enhanced ara-C cytotoxicity

NCT ID: NCT00410423 Completed - Clinical trials for Refractory Acute Leukemia

Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

Start date: January 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Based on what is known about it's mechanism of action, bortezomib is presumed to make other chemotherapy drugs work better. This study examines the use of bortezomib in combination with an already effective chemotherapy regimen that is used to treat leukemias that have relapsed or been refractory to treatment.